FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387379704> ?p ?o ?g. }

• W4387379704 abstract "Abstract Disclosure: G. Schang: Employee; Self; 35Pharma Inc. M. Poujol de Molliens: Employee; Self; 35Pharma Inc. E. Brûlé: Employee; Self; 35Pharma Inc. C. Chauvet: Employee; Self; 35Pharma Inc. J. Denis: Employee; Self; 35Pharma Inc. A. Sours: Employee; Self; 35Pharma Inc. V. Ganesh: Employee; Self; 35Pharma Inc. G. Tremblay: Employee; Self; 35Pharma Inc. J. Schoelermann: Employee; Self; 35Pharma Inc. M. O'Connor-McCourt: Employee; Self; 35Pharma Inc. Introduction: Novel anti-obesity medications including incretin mimetics have revolutionized the pharmacotherapy of obesity and type 2 diabetes, leading to unprecedented weight loss and clinically meaningful improvement of glucose metabolism and cardiometabolic health. However, this loss of fat mass is accompanied by undesirable loss of lean body mass (LBM) which can account for 15 - 40% of overall weight loss. Loss of LBM by incretin-based therapies negatively impacts resting metabolic rate, leading to a weight loss plateau and often unsustainable results. The preservation, or even increase, of LBM is therefore a desirable treatment goal for obesity pharmacotherapy and improvement of overall health. Activins and growth differentiation factors (GDFs), which are members of the TGF-beta superfamily, are validated targets controlling body composition and metabolism. Specifically, blockade of activins and GDFs has anabolic effects in metabolically active tissues such as skeletal muscle and brown adipose tissue, while reducing white adipose tissue mass. Therefore, specific and selective blockade of activins and GDFs represents a novel anti-obesity treatment strategy which can act orthogonally to current anti-obesity medications. Aims and objectives: HS235 is an activin receptor ectodomain-based (ActR) Fc-fusion protein that has been rationally designed to attain optimal inhibition of ligands controlling body composition in obesity. Methods: A structure-assisted rational molecular engineering approach coupled with cell-based potency screening was employed to design HS235. In vivo target engagement and pharmacodynamic response to HS235 were assessed in mice by quantifying metabolic biomarkers including muscle hypertrophy, muscle and fat gene expression, as well as plasma metabolites. To further validate the anti-obesogenic potential of HS235, diet-induced obese (DIO) mice were injected with HS235, an incretin mimetic, or a combination of both. Fat mass, LBM, glucose metabolism, exercise tolerance, and biomarker readouts were assessed at the end of study. Results: In cell-based assays, HS235 potently and selectively neutralized activins and GDFs implicated in body composition. This translated to complete in vivo target engagement and pharmacodynamic response. In a DIO mouse model, both HS235 and the incretin mimetic significantly improved metabolic parameters and decreased fat mass, but only HS235 increased LBM, while incretin-based treatment led to LBM loss. Importantly, the addition of HS235 to the incretin mimetic prevented this loss of LBM. Conclusion: Potent and selective inhibition of activins and GDFs by HS235 represents a novel LBM preserving weight loss strategy. Collectively, these data support the development of HS235 as a novel anti-obesity agent that may also complement currently approved incretin-based medications. Presentation: Friday, June 16, 2023" @default.
• W4387379704 created "2023-10-06" @default.
• W4387379704 creator A5016404458 @default.
• W4387379704 creator A5023536473 @default.
• W4387379704 creator A5029035148 @default.
• W4387379704 creator A5036584692 @default.
• W4387379704 creator A5037955697 @default.
• W4387379704 creator A5058644101 @default.
• W4387379704 creator A5061652560 @default.
• W4387379704 creator A5066827889 @default.
• W4387379704 creator A5075549153 @default.
• W4387379704 creator A5079219977 @default.
• W4387379704 date "2023-10-01" @default.
• W4387379704 modified "2023-10-18" @default.
• W4387379704 title "FRI017 Precision-engineered Activin And GDF Ligand Trap HS235: A Novel Lean Mass-preserving Treatment for Obesity" @default.
• W4387379704 doi "https://doi.org/10.1210/jendso/bvad114.028" @default.
• W4387379704 hasPublicationYear "2023" @default.
• W4387379704 type Work @default.
• W4387379704 citedByCount "0" @default.
• W4387379704 crossrefType "journal-article" @default.
• W4387379704 hasAuthorship W4387379704A5016404458 @default.
• W4387379704 hasAuthorship W4387379704A5023536473 @default.
• W4387379704 hasAuthorship W4387379704A5029035148 @default.
• W4387379704 hasAuthorship W4387379704A5036584692 @default.
• W4387379704 hasAuthorship W4387379704A5037955697 @default.
• W4387379704 hasAuthorship W4387379704A5058644101 @default.
• W4387379704 hasAuthorship W4387379704A5061652560 @default.
• W4387379704 hasAuthorship W4387379704A5066827889 @default.
• W4387379704 hasAuthorship W4387379704A5075549153 @default.
• W4387379704 hasAuthorship W4387379704A5079219977 @default.
• W4387379704 hasBestOaLocation W43873797041 @default.
• W4387379704 hasConcept C120863210 @default.
• W4387379704 hasConcept C126322002 @default.
• W4387379704 hasConcept C134018914 @default.
• W4387379704 hasConcept C147583825 @default.
• W4387379704 hasConcept C162324750 @default.
• W4387379704 hasConcept C171089720 @default.
• W4387379704 hasConcept C187736073 @default.
• W4387379704 hasConcept C26077564 @default.
• W4387379704 hasConcept C2776214593 @default.
• W4387379704 hasConcept C2777180221 @default.
• W4387379704 hasConcept C511355011 @default.
• W4387379704 hasConcept C544821477 @default.
• W4387379704 hasConcept C555293320 @default.
• W4387379704 hasConcept C71924100 @default.
• W4387379704 hasConceptScore W4387379704C120863210 @default.
• W4387379704 hasConceptScore W4387379704C126322002 @default.
• W4387379704 hasConceptScore W4387379704C134018914 @default.
• W4387379704 hasConceptScore W4387379704C147583825 @default.
• W4387379704 hasConceptScore W4387379704C162324750 @default.
• W4387379704 hasConceptScore W4387379704C171089720 @default.
• W4387379704 hasConceptScore W4387379704C187736073 @default.
• W4387379704 hasConceptScore W4387379704C26077564 @default.
• W4387379704 hasConceptScore W4387379704C2776214593 @default.
• W4387379704 hasConceptScore W4387379704C2777180221 @default.
• W4387379704 hasConceptScore W4387379704C511355011 @default.
• W4387379704 hasConceptScore W4387379704C544821477 @default.
• W4387379704 hasConceptScore W4387379704C555293320 @default.
• W4387379704 hasConceptScore W4387379704C71924100 @default.
• W4387379704 hasIssue "Supplement_1" @default.
• W4387379704 hasLocation W43873797041 @default.
• W4387379704 hasOpenAccess W4387379704 @default.
• W4387379704 hasPrimaryLocation W43873797041 @default.
• W4387379704 hasRelatedWork W1987413475 @default.
• W4387379704 hasRelatedWork W2008054780 @default.
• W4387379704 hasRelatedWork W2183630554 @default.
• W4387379704 hasRelatedWork W2514733910 @default.
• W4387379704 hasRelatedWork W3127173649 @default.
• W4387379704 hasRelatedWork W3134134177 @default.
• W4387379704 hasRelatedWork W3149563891 @default.
• W4387379704 hasRelatedWork W4366975589 @default.
• W4387379704 hasRelatedWork W4379526598 @default.
• W4387379704 hasRelatedWork W4382117200 @default.
• W4387379704 hasVolume "7" @default.
• W4387379704 isParatext "false" @default.
• W4387379704 isRetracted "false" @default.
• W4387379704 workType "article" @default.